{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T11:47:10Z","timestamp":1771760830432,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.eururo.2004.08.016","type":"journal-article","created":{"date-parts":[[2004,9,14]],"date-time":"2004-09-14T21:03:33Z","timestamp":1095195813000},"page":"731-740","source":"Crossref","is-referenced-by-count":56,"title":["Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care"],"prefix":"10.1016","volume":"46","author":[{"given":"Fred","family":"Saad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude C.","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2004.08.016_bib1","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase no. 5. Lyon: IARCPress; 2001. Available at: http:\/\/www-dep.iarc.fr\/globocan\/cdrom.htm. Accessed June 21, 2004."},{"key":"10.1016\/j.eururo.2004.08.016_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/qjmed\/hcg009","article-title":"How are we looking after prostate cancer?","volume":"96","author":"Waxman","year":"2003","journal-title":"Q J Med"},{"key":"10.1016\/j.eururo.2004.08.016_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.273.2.129","article-title":"Quality-of-life outcomes in men treated for localized prostate cancer","volume":"273","author":"Litwin","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2004.08.016_bib4","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","article-title":"Low bone mineral density in hormone-naive men with prostate carcinoma","volume":"91","author":"Smith","year":"2001","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1016\/j.eururo.2004.08.016_bib5","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z","article-title":"Biochemical markers and skeletal metastases","volume":"88","author":"Demers","year":"2000","journal-title":"Cancer"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2004.08.016_bib6","first-page":"180","article-title":"The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer","volume":"13","author":"Weinfurt","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib7","unstructured":"National osteoporosis foundation physician's guide osteoporosis: impact and overview. Available at: http:\/\/www.nof.org\/physguide\/impact_and_overview.htm. Accessed March 4, 2004."},{"key":"10.1016\/j.eururo.2004.08.016_bib8","first-page":"1521","article-title":"Osteoporosis in men","volume":"67","author":"Campion","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.eururo.2004.08.016_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00223-001-1045-7","article-title":"Mortality, morbidity, and assessment of fracture risk in male osteoporosis","volume":"69","author":"Johnell","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eururo.2004.08.016_bib10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s001980170017","article-title":"The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada","volume":"12","author":"Adachi","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eururo.2004.08.016_bib11","first-page":"1108","article-title":"Vertebral fractures: a hidden problem of osteoporosis","volume":"7","author":"Haczynski","year":"2001","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.eururo.2004.08.016_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF01626602","article-title":"Age-related hip fractures in men: clinical spectrum and short-term outcomes","volume":"5","author":"Poor","year":"1995","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eururo.2004.08.016_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1078-1439(03)00143-1","article-title":"Bone loss and the evolving role of bisphosphonate therapy in prostate cancer","volume":"21","author":"Higano","year":"2003","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-5347(05)68001-9","article-title":"Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength","volume":"163","author":"Van Veldhuizen","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2004.08.016_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","article-title":"Osteoporosis during androgen deprivation therapy for prostate cancer","volume":"60","author":"Smith","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.08.016_bib16","first-page":"316a","article-title":"The androgen deprivation syndrome (ADS): the incidence and severity in prostate cancer (PC) patients (PTS) receiving hormone blockade (HB)","volume":"17","author":"McDermed","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib18","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1210\/jc.86.6.2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2004.08.016_bib19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","article-title":"Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer","volume":"86","author":"Hatano","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2004.08.016_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0302-2838(03)00379-8","article-title":"Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment","volume":"44","author":"Morote","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2004.08.016_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","article-title":"Osteoporosis after orchiectomy for prostate cancer","volume":"157","author":"Daniell","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2004.08.016_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1634\/theoncologist.9-3-295","article-title":"Intermittent androgen deprivation therapy for prostate cancer","volume":"9","author":"Rashid","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2004.08.016_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.08.016_bib24","first-page":"198a","article-title":"The dynamics of bone mineral density during intermittent androgen suppression (IAS) in prostate cancer (PC) patients without bone metastases","volume":"21","author":"Jiang PYZ","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib25","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2004.08.016_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00223-001-1057-3","article-title":"The assessment of bone mass in men","volume":"69","author":"Lombardi","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eururo.2004.08.016_bib27","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1359\/jbmr.2001.16.12.2163","article-title":"Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture","volume":"16","author":"Chesnut","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2004.08.016_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF02210681","article-title":"Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview","volume":"14","author":"Kaufman","year":"1995","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.eururo.2004.08.016_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","article-title":"Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens","volume":"57","author":"Eriksson","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eururo.2004.08.016_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0090-4295(01)01252-3","article-title":"The role of diethylstilbestrol in the treatment of prostate cancer","volume":"58","author":"Malkowicz","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.08.016_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02550571","article-title":"High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate","volume":"30","author":"Ahmed","year":"1998","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2004.08.016_bib32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jcem-69-3-523","article-title":"Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling","volume":"69","author":"Stepan","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2004.08.016_bib33","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","article-title":"The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy","volume":"83","author":"Diamond","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2004.08.016_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eururo.2003.10.003","article-title":"Role of bisphosphonates in prostate cancer","volume":"45","author":"Saad","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2004.08.016_bib35","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2004.08.016_bib36","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib37","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2004.08.016_bib38","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2004.08.016_bib39","unstructured":"Saad F, Bukowski R, Lipton A, Colombo-Berra A, Delfina C, Rosen L, et al. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to prostate and renal cancer. Presented at: 39th Annual Meeting of the American Society of Clinical Oncology; May 31\u2013June 3, 2003; Chicago, Illinois. Available at: http:\/\/www.asco.org. Accessed January 14, 2004 [Abstract]."},{"issue":"Suppl","key":"10.1016\/j.eururo.2004.08.016_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cncr.11149","article-title":"Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma","volume":"97","author":"Smith","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2004.08.016_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0305-7372(03)00076-8","article-title":"Management of treatment-related osteoporosis in men with prostate cancer","volume":"29","author":"Smith","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2004.08.016_bib42","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2004.08.016_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","article-title":"The new bisphosphonate, Zometa\u00ae (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate","volume":"20","author":"Lipton","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1016\/j.eururo.2004.08.016_bib44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(02)02006-X","article-title":"Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer","volume":"61","author":"Smith","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.08.016_bib45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0302-2838(03)00366-X","article-title":"Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer","volume":"44","author":"See","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2004.08.016_bib46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S8756-3282(02)00670-1","article-title":"Bone mineral density and mortality in elderly men and women: the Rotterdam Study","volume":"30","author":"van der Klift","year":"2002","journal-title":"Bone"},{"issue":"Suppl","key":"10.1016\/j.eururo.2004.08.016_bib47","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2004.08.016_bib48","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s002590100533","article-title":"A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer","volume":"28","author":"Dafermou","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.eururo.2004.08.016_bib49","first-page":"399","article-title":"External beam radiotherapy in bone metastatic prostate cancer: impact on patients\u2019 pain relief and quality of life","volume":"10","author":"Di Lorenzo","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1016\/j.eururo.2004.08.016_bib50","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2004.08.016_bib51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib52","first-page":"2","article-title":"SWOG 99-16: randomized phase III trial of docetaxel (D)\/estramustine (E) versus mitoxantrone(M)\/prednisone(p) in men with androgen-independent prostate cancer (AIPCA)","volume":"23","author":"Petrylak","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib53","first-page":"2","article-title":"A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC)","volume":"23","author":"Eisenberger","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of bone metastases","volume":"5","author":"Coleman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2004.08.016_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/00015458.1998.12098427","article-title":"Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures","volume":"98","author":"Fourneau","year":"1998","journal-title":"Acta Chir Belg"},{"key":"10.1016\/j.eururo.2004.08.016_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF01053418","article-title":"Spinal cord compression in prostate cancer","volume":"23","author":"Osborn","year":"1995","journal-title":"J Neurooncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1026407010614","article-title":"The Caregiver Quality of Life Index-Cancer (CQOLC) scale: development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer","volume":"8","author":"Weitzner","year":"1999","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2004.08.016_bib58","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.eururo.2004.08.016_bib59","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib60","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2004.08.016_bib61","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2004.08.016_bib62","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2004.08.016_bib63","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"key":"10.1016\/j.eururo.2004.08.016_bib64","unstructured":"Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane Review). In: The Cochrane Library, Issue 2. Chichester (UK): John Wiley & Sons, Ltd.; 2004."},{"issue":"Suppl","key":"10.1016\/j.eururo.2004.08.016_bib65","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2004.08.016_bib66","article-title":"Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer","volume":"23","author":"Saad","year":"2004","journal-title":"Proc Am Soc Clin Oncol."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283804004166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283804004166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T18:12:09Z","timestamp":1624644729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283804004166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0302283804004166"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2004.08.016","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}